2022
Thrombosis questions from the inpatient wards
Goshua G, Bendapudi P, Lee A. Thrombosis questions from the inpatient wards. Hematology 2022, 2022: 481-490. PMID: 36485139, PMCID: PMC9819989, DOI: 10.1182/hematology.2022000384.Peer-Reviewed Original ResearchConceptsCancer-associated thrombosisInpatient wardsPurpura fulminansIntermediate-dose anticoagulationEtiology of thrombocytopeniaMajor clinical trialsCases of thrombosisCoronavirus disease 2019Recent prospective dataCOVID-19Antithrombin replacementAnticoagulation therapyAntiplatelet therapyAntithrombotic therapyAnticoagulation managementMicrovascular thrombosisPlasma transfusionHospitalized patientsAntiplatelet agentsThromboembolic diseasePlatelet countConsensus guidelinesProspective dataClinical trialsDisease 2019Immune checkpoint inhibitors for recurrent endometrial cancer
Mutlu L, Harold J, Tymon-Rosario J, Santin AD. Immune checkpoint inhibitors for recurrent endometrial cancer. Expert Review Of Anticancer Therapy 2022, 22: 249-258. PMID: 35176955, DOI: 10.1080/14737140.2022.2044311.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsRecurrent endometrial cancerCheckpoint inhibitorsEndometrial cancerEC patientsAdvanced/recurrent endometrial cancerPD-1/PD-L1 inhibitorsRecurrent EC patientsUse of chemotherapyCommon gynecologic malignancyMajor clinical trialsPD-L1 inhibitorsBiomarkers of responseViable treatment optionHuman cancer treatmentTumor microenvironment immunosuppressionRecurrent diseaseGynecologic malignanciesPD-1Clinical efficacyPatient populationTreatment optionsTumor immunogenicityRecent trialsClinical trials
2020
Sex-Specific Outcomes in Cardiovascular Device Evaluations
Ghare MI, Tirziu D, Abbott JD, Altin E, Yang Y, Ng V, Grines C, Lansky A. Sex-Specific Outcomes in Cardiovascular Device Evaluations. Journal Of Women's Health 2020, 29: 1246-1255. PMID: 32543268, PMCID: PMC9545802, DOI: 10.1089/jwh.2019.8068.Peer-Reviewed Original ResearchConceptsCoronary revascularizationHeart failureClinical trialsDevice trialsMajor clinical trialsStructural heart diseaseSex-specific outcomesBenefit/risk assessmentCardiac resynchronization defibrillatorImplantable cardioverter defibrillatorVentricular assist deviceBest available careDrug eluting stentsBetter treatment recommendationsCardiovascular outcomesDevice therapyTreatment recommendationsHeart diseaseCardioverter defibrillatorDevice clinical trialsTreatment selectionAvailable careAssist deviceNarrative reviewEluting stents
2016
ACR Appropriateness Criteria® Hodgkin Lymphoma—Unfavorable Clinical Stage I and II
Roberts KB, Younes A, Hodgson DC, Advani R, Dabaja BS, Dhakal S, Flowers CR, Ha CS, Hoppe BS, Mendenhall NP, Metzger ML, Plastaras JP, Shapiro R, Smith SM, Terezakis SA, Winkfield KM, Constine LS. ACR Appropriateness Criteria® Hodgkin Lymphoma—Unfavorable Clinical Stage I and II. American Journal Of Clinical Oncology 2016, 39: 384-395. PMID: 27299425, DOI: 10.1097/coc.0000000000000294.Peer-Reviewed Original ResearchConceptsHodgkin's lymphomaAppropriateness CriteriaEvidence-based treatment algorithmEarly-stage Hodgkin lymphomaAppropriateness of imagingClinical stage IRadiation treatment volumesMajor clinical trialsACR Appropriateness CriteriaRadiology Appropriateness CriteriaMultidisciplinary expert panelEvidence-based guidelinesClassic Hodgkin lymphomaInvolved-site radiotherapySpecific clinical conditionsCurrent medical literatureAppropriate treatment decisionsLong-term toxicityCurrent treatment schemesRadiation dose prescriptionUnfavorable presentationSequential chemotherapyPeer-reviewed journalsPrognostic factorsTherapy intensitySelective Hearing: Physician‐Ownership and Physicians’ Response to New Evidence
Howard D, David G, Hockenberry J. Selective Hearing: Physician‐Ownership and Physicians’ Response to New Evidence. Journal Of Economics & Management Strategy 2016, 26: 152-168. DOI: 10.1111/jems.12178.Peer-Reviewed Original Research
2014
Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes
Zahr A, Aldin E, Komrokji RS, Zeidan AM. Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes. Journal Of Blood Medicine 2014, 6: 1-16. PMID: 25565910, PMCID: PMC4278786, DOI: 10.2147/jbm.s50482.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMyelodysplastic syndromeClinical trialsClinical utilityRed blood cell transfusion requirementsLower-risk myelodysplastic syndromesHigh-risk myelodysplastic syndromeActivity of lenalidomideDifferent prognostic scoresMajor clinical trialsPeripheral blood cytopeniasEfficacy of lenalidomideClonal hematopoietic disordersQuality of lifeMechanism of actionMDS managementTransfusion requirementsBlood cytopeniasPrognostic scoreClinical outcomesRisk stratificationMechanisms of resistanceIneffective hematopoiesisLenalidomideDrug lenalidomideLeukemic transformation
2010
Intravenous (IV) Thrombolysis
Nogueira R, Schwamm L. Intravenous (IV) Thrombolysis. 2010, 221-243. DOI: 10.1007/978-3-642-12751-9_11.Peer-Reviewed Original Research
2009
Racial and Gender Trends in the Use of Implantable Cardioverter‐Defibrillators Among Medicare Beneficiaries Between 1997 and 2003
Chan PS, Birkmeyer JD, Krumholz HM, Spertus JA, Nallamothu BK. Racial and Gender Trends in the Use of Implantable Cardioverter‐Defibrillators Among Medicare Beneficiaries Between 1997 and 2003. Congestive Heart Failure 2009, 15: 51-57. PMID: 19379450, PMCID: PMC2921372, DOI: 10.1111/j.1751-7133.2009.00060.x.Peer-Reviewed Original Research
2004
Use of Low Molecular Weight Heparins and Glycoprotein IIb/IIIa Inhibitors in Patients with Chronic Kidney Disease
Perazella M, Mosenkis A, Berns J. Use of Low Molecular Weight Heparins and Glycoprotein IIb/IIIa Inhibitors in Patients with Chronic Kidney Disease. Seminars In Dialysis 2004, 17: 411-416. PMID: 15461751, DOI: 10.1111/j.0894-0959.2004.17351.x.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngina, UnstableDiabetes Mellitus, Type 2Diabetic NephropathiesDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationFollow-Up StudiesHeparin, Low-Molecular-WeightHumansKidney Failure, ChronicMalePlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexRisk AssessmentTreatment OutcomeConceptsLow molecular weight heparinIIb/IIIa inhibitorsChronic kidney diseaseAcute coronary syndromeEnd-stage renal diseaseMolecular weight heparinWeight heparinKidney diseaseGlycoprotein IIb/IIIa inhibitorsGP IIb/IIIa inhibitorsSafety of LMWHLarge prospective trialsMajor clinical trialsCardiac causesCoronary syndromeAppropriate dosingProspective trialRenal diseaseKidney functionAggressive interventionClinical benefitClinical trialsPatientsSignificant impairmentDisease
2003
HER-2/neu testing in breast cancer.
Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Hortobagyi GN. HER-2/neu testing in breast cancer. American Journal Of Clinical Pathology 2003, 120 Suppl: s53-71. PMID: 15298144, DOI: 10.1309/949fpq1aq3p0rlc0.Peer-Reviewed Original ResearchConceptsBreast cancerNeu testingNeu statusProspective clinical outcome studyTrastuzumab-based therapyMajor clinical trialsEarly clinical stagePredictors of responseClinical outcome studiesBreast cancer specimensAdvanced diseaseClinical responseClinical stageClinical trialsStandards of practiceCancer specimensImmunohistochemical analysisOutcome studiesPotential efficacyCancerSitu hybridization techniqueRecent evidenceTherapySitu hybridization methodExcellent results
2001
Glycohemoglobin: A Primary Predictor of the Development or Reversal of Complications of Diabetes Mellitus
Krishnamurti U, Steffes M. Glycohemoglobin: A Primary Predictor of the Development or Reversal of Complications of Diabetes Mellitus. Clinical Chemistry 2001, 47: 1157-1165. PMID: 11427445, DOI: 10.1093/clinchem/47.7.1157.Peer-Reviewed Original ResearchConceptsGlycemic controlDiabetes mellitusClinical trialsDiabetic patientsType 2 diabetes mellitusReversal of complicationsMajor clinical trialsLong-term microProgression of complicationsImportant prognostic informationMajor health problemGlycohemoglobin measurementsMeasurement of glycohemoglobinTranslation of findingsMacrovascular complicationsDiabetic complicationsPrognostic informationDiabetic therapyComplicationsMellitusClinical practiceHealth problemsGlycohemoglobinType 1ProgressionThe Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease
Freedberg K, Losina E, Weinstein M, Paltiel A, Cohen C, Seage G, Craven D, Zhang H, Kimmel A, Goldie S. The Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease. New England Journal Of Medicine 2001, 344: 824-831. PMID: 11248160, DOI: 10.1056/nejm200103153441108.Peer-Reviewed Original ResearchMeSH KeywordsAIDS-Related Opportunistic InfectionsAnti-HIV AgentsCD4 Lymphocyte CountComputer SimulationCost-Benefit AnalysisDirect Service CostsDisease ProgressionDrug CostsDrug Therapy, CombinationHealth Care CostsHIV InfectionsHumansLife ExpectancyModels, BiologicalQuality-Adjusted Life YearsRNA, ViralUnited StatesValue of LifeConceptsQuality-adjusted yearThree-drug therapyCombination antiretroviral therapyCD4 cell countQuality of lifeAntiretroviral therapyHIV diseaseClinical benefitDrug costsLife expectancyCell countInitial CD4 cell countThree-drug antiretroviral regimensHuman immunodeficiency virus (HIV) infectionHIV RNA levelsPerson lifetime costsImmunodeficiency virus infectionMajor clinical trialsDirect medical costsStandard of careProgression of diseaseLifetime direct medical costsCost-effectiveness ratioServices Utilization SurveyCost effectiveness
1995
Medical Therapy and Prognosis in Chronic Heart Failure Lessons from Clinical Trials
Ramahi T, Lee F. Medical Therapy and Prognosis in Chronic Heart Failure Lessons from Clinical Trials. Cardiology Clinics 1995, 13: 5-26. PMID: 7796432, DOI: 10.1016/s0733-8651(18)30058-4.Peer-Reviewed Original ResearchConceptsChronic heart failureLeft ventricular dysfunctionIntermediate-term improvementVentricular dysfunctionClinical trialsHeart failureLong-term improvementHemodynamic improvementLong-term effectsFunctional capacityShort-term hemodynamic improvementSystolic left ventricular dysfunctionChronic left ventricular dysfunctionACE inhibitor therapyRole of diureticsImmediate symptomatic reliefMajor clinical trialsSympathetic nervous systemMarker of prognosisGoal of therapyPure vasodilationAldosterone systemDirect vasodilatorAcute stabilizationPharmacologic therapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply